State Street Corp Sells 50,883 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

State Street Corp trimmed its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 3.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,472,955 shares of the biotechnology company's stock after selling 50,883 shares during the period. State Street Corp owned approximately 5.44% of Arcturus Therapeutics worth $34,187,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ARCT. nVerses Capital LLC acquired a new stake in Arcturus Therapeutics in the third quarter worth $42,000. Quest Partners LLC increased its position in shares of Arcturus Therapeutics by 3,283.5% in the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock valued at $90,000 after buying an additional 3,579 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock worth $121,000 after buying an additional 2,038 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Arcturus Therapeutics during the second quarter worth about $142,000. Finally, Point72 DIFC Ltd acquired a new position in Arcturus Therapeutics in the second quarter valued at about $188,000. Institutional investors own 94.54% of the company's stock.

Insider Activity at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the transaction, the chief operating officer now directly owns 435,334 shares in the company, valued at $9,037,533.84. This represents a 2.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 15.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ARCT shares. HC Wainwright reaffirmed a "buy" rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Arcturus Therapeutics has a consensus rating of "Buy" and a consensus price target of $66.75.

Arcturus Therapeutics Stock Up 4.3 %

Shares of NASDAQ:ARCT traded up $0.64 during mid-day trading on Friday, reaching $15.48. 812,427 shares of the stock were exchanged, compared to its average volume of 467,977. The stock's 50 day simple moving average is $18.24 and its 200-day simple moving average is $21.48. Arcturus Therapeutics Holdings Inc. has a one year low of $14.30 and a one year high of $45.00. The company has a market cap of $419.31 million, a P/E ratio of -6.97 and a beta of 2.62.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.44. The company had revenue of $41.67 million during the quarter, compared to analysts' expectations of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same period last year, the business earned ($0.61) EPS. Analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.